Inivata raises £40M to fund U.S. lung cancer blood test rollout

red blood cells
Inivata recently received a Medicare coverage determination for its InVisionFirst diagnostic, to examine multiple genetic mutations in patients with advanced non-small cell lung cancer. (Pixabay)

Liquid biopsy developer Inivata has secured a total of £39.8 million, or about $52.6 million, to help commercialize its DNA sequencing test through an extended series B round.

First closed in August 2018, the overall round saw funding from the company’s returning backers—including Johnson & Johnson Innovation, Cambridge Innovation Capital, IP Group, and Woodford Patient Capital Trust—plus its new investor, RT Ventures.

Based in Cambridge, U.K., and Research Triangle Park, North Carolina, Inivata plans to use the proceeds to support the U.S. rollout of its InVisionFirst molecular diagnostic, which recently received a Medicare coverage determination to examine genetic mutations in patients with advanced non-small cell lung cancer.


AI Innovations for Life Science and Healthcare Summit East

Join the expert speaking faculty of over 30 life science, healthcare, and tech professionals on June 13–14, 2019, in Philadelphia, as we elevate clinical trial operations, healthcare outcomes, and supply chain implementation through AI. Use Discount Code 796819FIERCE to save 15% off the standard registration rate.

The financing will also help the company develop its InVision liquid biopsy platform in new indications, the company said.

RELATED: Genomics England taps Inivata for liquid biopsy pilot study

“Inivata has made great progress since our first investment when it was spun out of Cancer Research UK’s laboratories in Cambridge,” Cambridge Innovation Capital Investment Director Michael Anstey, Ph.D., said in a statement. “We are delighted to have helped Inivata develop from a startup through to commercializing its products.”

Inivata previously raised £31.5 million, or about $45 million, in its 2016 series A round. Its circulating tumor DNA test looks for cancer-related mutations in the blood, to assist physicians in assigning a specific therapy and monitor treatment progress.

Suggested Articles

Scientists characterized the structures of melatonin receptors, which they say could enable design of better drugs to treat sleep disorders.

The FDA cleared Current Health’s wearable tracker, designed to be taken home from the hospital after acute care to track a patient’s recovery.

Gilead’s NASH candidate selonsertib did worse than placebo at reducing scarring in NASH patients with stage 3 fibrosis.